|
August 2005 Features:
SET-HD - The SET-HD working group is continuing to prepare detailed reviews of the approximately 40 compounds selected for initial evaluation based on their potential to move quickly into clinical trials. 24 compound reviews have been completed. Please see SET-HD Updates.
COHORT – Cooperative Huntington’s Observational Research Trial
The Huntington Project is about to kick off a long-term observational study to address a wide variety of research questions in Huntington’s disease. The study will collect information from people with HD and from family members. Participants will have a clinical evaluation and will also have the option of contributing family history information and blood samples for future HD studies. Enrollment is set to begin soon, and will take place initially at 45 North American and Australian Huntington Study Group (HSG) sites. Learn more about COHORT and how you can be a part of this important study.
TREND-HD: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects with Mild to Moderate Huntington’s Disease
The Huntington Study Group (HSG) is conducting a study of the research medication ethyl-EPA in persons 35 years of age or older who have mild to moderate Huntington’s disease (HD). See TREND-HD for more information.
PHEND-HD: Phenylbutyrate Development for Huntington’s Disease - A Multi-center, Double-Blind, Placebo-Controlled Study with Open-Label Follow-Up to Determine the Safety & Tolerability of Phenylbutyrate in Subjects with Huntington’s Disease
The Huntington Study Group (HSG) is conducting a study of of phenylbutyrate. See PHEND-HD for more information.
|